LABCORP HOLDINGS INC. Posts Synchronized Revenue and Earnings Gains Across Both Reporting Windows in Interim Filing

Bottom line

- LABCORP HOLDINGS INC., identified by 10-Q period-ended-2026-06-30 under accession 0000920148-26-000175 (CIK 0000920148, ticker LH), posted a profit-to-profit improvement on both the three-month and six-month year-to-date windows of its interim filing, with higher revenues, higher operating income, higher net income attributable to parent, and higher diluted earnings per share against the prior-year comparatives. The reader can sanity-check the directional pattern against a peer interim such as REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, where a different healthcare-services issuer also prints synchronized revenue and earnings growth. - The interim 10-Q for the three-month reporting period the three months ended June 30, 2026 shows Revenues of $3,731,100,000 USD versus the prior-year comparative of $3,527,300,000 USD, an authorized increase on a positive base; Net Income (Loss) Attributable to Parent of $298,700,000 USD against $237,900,000 USD, an authorized increase and an authorized profit-to-profit transition; Operating Income (Loss) of $451,600,000 USD versus $394,500,000 USD, an authorized increase and an authorized profit-to-profit transition; and Earnings Per Share, Diluted of $3.64 per diluted share USD/SHARES against $2.84 per diluted share USD/SHARES, an authorized increase and an authorized profit-to-profit transition. - The year-to-date window the six months ended June 30, 2026 mirrors that picture: Revenues of $7,268,700,000 USD versus the prior-year comparative of $6,872,400,000 USD, an authorized increase on a positive base; Net Income (Loss) Attributable to Parent of $576,500,000 USD against $450,700,000 USD, an authorized increase and an authorized profit-to-profit transition; Operating Income (Loss) of $832,400,000 USD versus $720,500,000 USD, an authorized increase and an authorized profit-to-profit transition; and Earnings Per Share, Diluted of $6.99 per diluted share USD/SHARES against $5.36 per diluted share USD/SHARES, an authorized increase and an authorized profit-to-profit transition.

MANAGEMENT COMMENTARY: - Management frames LABCORP HOLDINGS INC. as a global laboratory-services leader organized into two reportable segments, Diagnostics Laboratories and Biopharma Laboratory Services, with interim results stated as not necessarily indicative of a full-year outcome and all adjustments described as normal and recurring. - The notes flag a recent FASB accounting pronouncement on credit-losses measurement that did not have a material impact, alongside a separate software-development accounting pronouncement whose impact is still being assessed by the Company.

- The combined picture on the two windows is a synchronized directional improvement across revenue, operating profit, net income, and diluted EPS, each moving on a positive base with a profit-to-profit transition, which is the canonical signature of an interim period that improved on every top-line and bottom-line metric that this catalog covers.

- No counter-evidence is presented in the filing evidence; the only directional statements the catalog authorizes are the increases listed above, and every current period is a profit against a profit in the prior period.

UNKNOWN: - The filing evidence contains no peer or industry comparison.. - The filing evidence does not attribute this change to any single cause..

Financial performance

- Revenues for LABCORP HOLDINGS INC. in the three-month window the three months ended June 30, 2026 came in at $3,731,100,000 USD, against $3,527,300,000 USD in the prior-year window, an authorized year-over-year increase; the prior-year base and the current quarter are both positive, so the headline is a simple expansion of the top line. - Revenues for the six-month year-to-date window the six months ended June 30, 2026 were $7,268,700,000 USD, compared with $6,872,400,000 USD for the six months ended June 30, 2025, again an authorized year-over-year increase on a positive-to-positive basis.

- Operating Income (Loss) for the quarter was $451,600,000 USD, against $394,500,000 USD; the authorized direction is an increase, with the current quarter remaining profitable relative to a profitable prior-year quarter, framing the result as a profit-to-profit transition. - Operating Income (Loss) for the six-month window was $832,400,000 USD, against $720,500,000 USD; the authorized direction is likewise an increase, with both periods in profit territory. - Net Income (Loss) Attributable to Parent for the quarter was $298,700,000 USD, against $237,900,000 USD; the authorized direction is an increase on a profit-to-profit basis.

- Net Income (Loss) Attributable to Parent for the six-month window was $576,500,000 USD, against $450,700,000 USD; the authorized direction is an increase, again profit-to-profit. 84 per diluted share USD/SHARES, an authorized increase; both periods sit on the profit side of the ledger, marking a profit-to-profit transition. 36 per diluted share USD/SHARES, also an authorized increase with a profit-to-profit label.

- The accounting context is the standard interim package under 10-Q for period-ended-2026-06-30 filed under accession 0000920148-26-000175 by entity 0000920148; management states the unaudited Condensed Consolidated Financial Statements reflect all normal recurring adjustments, that interim results are not necessarily indicative of a full year, and that the December year-end balance sheet was derived from the audited annual statements but omits certain GAAP disclosures, so the reader is expected to read this report alongside the Annual Report.

- Two segment pillars, Diagnostics Laboratories and Biopharma Laboratory Services, frame how the revenue figure above is produced, while investments in which the Company lacks significant influence are carried at fair value, or at cost minus impairment adjusted for observable price changes where fair value is not readily determinable, and foreign operating subsidiaries use the local currency as the functional currency with translation adjustments parked in Accumulated other comprehensive loss. - Recent ASU adoptions cited in the notes — Credit Losses, Internal-Use Software, Government Grants, Interim Reporting, and an incremental improvements standard — were each described as immaterial or still under assessment; the Credit Losses pronouncement is flagged as not having a material impact, and the others are described as under assessment rather than quantified.

- Guidance and forward expectations are not provided as discrete quantitative anchors in the quoted evidence; the filing offers only the standard interim caveat that quarterly results are not necessarily indicative of a full year. The filing evidence does not attribute this change to any single cause. - Peer and industry comparison baselines are not supplied in the filing evidence, so no external benchmark is asserted against the revenue or operating figures above.

The filing evidence contains no peer or industry comparison. - For cross-filing context, readers comparing like-for-like interim expansions can review REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing to contrast a different profit-to-profit interim pattern, while loss-side interim dynamics are illustrated by Arena Group Swings to Loss as Revenue and Operating Profit Soften in Interim Filing, neither of which substitutes for an industry-specific read on Labcorp.

Operating drivers and segments

The Company reports its business in two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), with the ED (Early Development) reporting unit sitting inside BLS. Goodwill impairment language in the source narrative describes a cumulative BLS-segment charge primarily tied to that ED reporting unit, which is the only segment-level color the filing evidence supplies.

For the consolidated picture, Revenues came in at $3,731,100,000 USD for the three months ended June 30, 2026 versus $3,527,300,000 USD for the three months ended June 30, 2025, and Operating Income (Loss) was $451,600,000 USD for the three months ended June 30, 2026 versus $394,500,000 USD for the three months ended June 30, 2025. On the year-to-date window, Revenues were $7,268,700,000 USD for the six months ended June 30, 2026 versus $6,872,400,000 USD for the six months ended June 30, 2025, with Operating Income (Loss) of $832,400,000 USD for the six months ended June 30, 2026 against $720,500,000 USD for the six months ended June 30, 2025. Both the quarter and half-year revenue and operating-income lines are authorized to be characterized as higher than the prior-year comparative, with operating income remaining a profit on both windows — a profit-to-profit transition. No segment-level revenue, margin, or volume figures appear in the filing evidence, so Dx-versus-BLS performance cannot be broken out from this draft.

Management describes the Company as a global leader in innovative and comprehensive laboratory services, providing diagnostics and drug-development capabilities that help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company states that it reports in two segments, Diagnostics Laboratories and Biopharma Laboratory Services. Management also notes a cumulative goodwill impairment primarily representing the goodwill of the ED reporting unit within the BLS segment, and that the BLS-segment context is where that charge concentrates. Management further indicates that the goodwill-impairment language is the segment-level commentary offered; segment-level revenue, organic-growth, pricing, mix, and margin walk are not provided in the quoted material.

Independent read of the evidence supports a single clean claim: at the consolidated level, both top-line and operating profit moved higher year over year on the quarter and the half-year windows, and operating income stayed profitable. The filing evidence does not attribute that improvement to any single cause. The only segment-level color is the ED-unit goodwill impairment inside BLS, which the source narrative does not link to current-period operating results. Peer or industry comparisons are not present in the filing evidence. For a cross-issuer read on a peer earnings print, REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing sits in the link inventory, though no head-to-head comparison can be made from this filing alone.

Cash flow and capital

- Operating cash flow for the six-month year-to-date window, on the machine-checked ledger, declined versus the prior-year comparative, though both windows remained in positive territory. Investing activities likewise stayed negative on both sides of the comparison, with the current period's outflow deeper than the prior year. - Reported fact: Net Cash Provided by (Used in) Operating Activities of $637,000,000 USD for the six months ended June 30, 2026, compared with $639,100,000 USD for the six months ended June 30, 2025.

- Reported fact: Net Cash Provided by (Used in) Investing Activities of -$688,300,000 USD for the six months ended June 30, 2026, compared with -$430,100,000 USD for the six months ended June 30, 2025. - Financing activities stayed negative on both windows, with the current-period outflow larger than a year ago, pointing to greater capital returns to shareholders and/or heavier debt activity, on a directionally consistent cadence with the repurchase and dividend lines below. - Reported fact: Net Cash Provided by (Used in) Financing Activities of -$339,400,000 USD for the six months ended June 30, 2026, compared with -$1,107,100,000 USD for the six months ended June 30, 2025.

- In the capital-return bucket, payments for repurchase of common stock rose against the prior-year comparative, while payments of dividends declined relative to the same prior-year window. Both lines remained positive in absolute terms, and the cited purchase-and-redemption debt activity earlier in the reporting period anchors the broader capital-allocation story. - Reported fact: Payments for Repurchase of Common Stock of $451,800,000 USD for the six months ended June 30, 2026, compared with $200,000,000 USD for the six months ended June 30, 2025.

- Reported fact: Payments of Dividends of $119,900,000 USD for the six months ended June 30, 2026, compared with $121,500,000 USD for the six months ended June 30, 2025. - Investing outflows included stepped-up spending on property, plant, and equipment year over year, even after netting the cash deployed for various business and asset acquisitions closed during the six months and the pending Empire City Laboratories transaction disclosed in the cited acquisition note. - Reported fact: Payments to Acquire Property, Plant, and Equipment of $252,600,000 USD for the six months ended June 30, 2026, compared with $203,900,000 USD for the six months ended June 30, 2025.

- On the balance sheet, cash and cash equivalents stood at $141,800,000 USD as of the balance sheet date of June 30, 2026, while long-term debt, excluding current maturities, was reported at $5,857,600,000 USD at the same balance sheet date. The senior revolving credit facility, which is permitted to be used for general corporate purposes including working capital, capital expenditures, funding of share repurchases and certain other payments, acquisitions, and other investments, was amended and restated during the period and supports the liquidity behind these flows.

- Counter-evidence / unknowns: the filing does not attribute the operating-cash decline, the wider investing outflow, or the higher share-repurchase spend to any single cause; readers looking for a peer benchmark or industry comparison will not find one in the filing. - Investors monitoring how aggressive the repurchase cadence has become against steady dividend outflows may want to cross-check this six-month return-of-capital picture against the broader insurer/managed-care interim pattern in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing before drawing conclusions.

Peer and historical context

Year-over-year comparisons within the filing indicate a generally constructive trajectory on both the three-month and six-month windows. Revenues, Operating Income, and Net Income each moved higher against the prior-year comparative on both reporting horizons, with Net Income remaining in profit on both sides of every comparison (no quarter or year-to-date window shows a sign flip). Operating cash flow, by contrast, declined on the year-to-date comparison even though it remained positive in absolute terms, which is a different shape than the income-statement line items above it. That divergence between declining cash from operations and rising accrual-based profit is the most distinctive cross-line pattern in the year-over-year picture for LABCORP HOLDINGS INC. as filed under 10-Q for period-ended-2026-06-30 in accession 0000920148-26-000175.

- The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison. - The filing evidence does not attribute this change to any single cause. The filing evidence does not attribute this change to any single cause. - Operating cash flow declined on the year-to-date comparison while every profit-line item increased, so the cash-conversion picture is not strictly aligned with the reported earnings direction. - The reported values include an "(omitted)" tag in several places, meaning exact magnitudes cannot be reconstructed from this excerpt; only the direction and sign relative to the prior-year comparative are usable.

Historical read across the windows: - On the quarter view, Revenues, Operating Income, and Net Income all registered higher readings than the prior-year quarter, and Net Income stayed in profit territory on both sides of the comparison. - On the year-to-date view, Revenues, Operating Income, and Net Income again ran higher than the prior-year year-to-date window, with Net Income again retaining a profit designation on both sides. - Operating cash flow on the year-to-date comparison moved lower in absolute terms, even while remaining positive; this is the one authorized year-over-year direction in the cash-flow group that runs counter to the income-statement direction. - No peer or industry benchmark is available inside this filing; cross-company comparisons must therefore be sought outside the filing evidence.

Scenario analysis

Under the base case, LABCORP HOLDINGS INC. (LH) carries forward the reported year-to-date and quarter trend on roughly the same slope. The three-month Revenues line for the three months ended June 30, 2026 came in at $3,731,100,000 USD, higher than the prior-year the three months ended June 30, 2025 reading of $3,527,300,000 USD, and the six-month Revenues line for the six months ended June 30, 2026 came in at $7,268,700,000 USD, higher than the prior-year the six months ended June 30, 2025 reading of $6,872,400,000 USD. Net Income (Loss) Attributable to Parent for the same windows was $298,700,000 USD versus $237,900,000 USD and $576,500,000 USD versus $450,700,000 USD, with the authorized direction calling for an increase on both windows. In the base view, no major policy, reimbursement, or volume shock interrupts that path, and management's continuing capital deployment, as flagged in the cited notes on acquisitions and credit facility changes, stays on its existing cadence.

In the upside case, revenue and earnings growth on both reporting windows extends beyond the authorized year-over-year direction, helped by the integration of businesses acquired during the six months just closed and by the announced Empire City Laboratories, Inc. transaction expected to close in the third quarter, both described in the cited note on business acquisitions. Capital structure flexibility, including the senior revolving credit facility referenced in the cited note on debt and the accounts receivable securitization facility entered into with PNC Bank, National Association, supports the working capital and share repurchase capacity discussed under the same item. If those levers compound with continued top-line gains, Net Income (Loss) Attributable to Parent and Operating Income (Loss), both authorized to increase on a profit-to-profit basis for the three months ended June 30, 2026 versus the three months ended June 30, 2025 and for the six months ended June 30, 2026 versus the six months ended June 30, 2025, could widen further, and Earnings Per Share, Diluted, also authorized to increase on both windows, could accelerate.

The downside case focuses on a deceleration rather than a reversal. The filing evidence does not show a profit-to-loss transition on any of the authorized comparisons, so the worst-case framing here is one of softer growth. Adverse moves in allowance for credit losses on Accounts receivable, net and Unbilled services, net, or delays in the Empire City Laboratories, Inc. closing, would weigh on Revenues and on Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 and the six months ended June 30, 2026. The goodwill balance, which the cited note flags as concentrated in the ED reporting unit within the BLS segment, is another sensitivity to monitor.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Risks and what to watch

- **Reported facts:** Both revenue and net income attributable to the parent increased year over year in the quarterly and year-to-date reporting windows. Revenue was $3,527,300,000 in the three months ended June 30, 2025 and $3,731,100,000 in the three months ended June 30, 2026. It was $6,872,400,000 in the six months ended June 30, 2025 and $7,268,700,000 in the six months ended June 30, 2026.

Net income attributable to the parent was $237,900,000 in the three months ended June 30, 2025 and $298,700,000 in the three months ended June 30, 2026. It was $450,700,000 in the six months ended June 30, 2025 and $576,500,000 in the six months ended June 30, 2026. The available evidence therefore does not show a top-line or bottom-line contraction on either comparative window.

- **Management explanations:** The filing describes a pending transaction that is expected to close in the third quarter, subject to customary closing conditions and regulatory approvals. It also describes financing activity involving term-loan proceeds, redemption of senior notes, a revolving credit facility, and a newly established accounts-receivable securitization facility. These disclosures indicate execution and funding considerations, but the filing excerpt does not quantify their prospective effect on revenue, earnings, liquidity, leverage, or transaction completion.

- **Analyst inference:** The simultaneous year-over-year increases in revenue and net income suggest that earnings strengthened alongside reported sales on both the quarter and year-to-date comparisons. This is a directional observation, not evidence that operating leverage, pricing, volume, acquisitions, or any other specific driver produced the improvement. - **Counter-evidence:** Despite the positive reported comparisons, the filing highlights cumulative goodwill impairment concentrated primarily in the ED reporting unit within the BLS segment.

That disclosure is relevant to asset quality and future earnings risk, although the filing evidence does not provide enough information to determine whether impairment recurred, increased, or reversed during the period. The excerpt also identifies potentially dilutive shares arising from stock options, restricted stock units, and performance share awards, which may affect per-share outcomes even when attributable net income increases. - **Unknowns:** The filing excerpt does not provide operating margin, cash flow, segment revenue, transaction consideration, expected synergies, regulatory status, pro-forma leverage, or a complete explanation of the impairment.

The filing evidence does not attribute this change to any single cause. - **Next watch:** Track whether the pending transaction closes on the expected schedule, how financing costs and any acquired operations affect future earnings, whether the securitization facility changes reported liquidity or borrowing capacity, and whether the ED reporting unit produces further impairment charges. Readers should also monitor whether revenue and attributable net income continue to increase in the next quarterly and year-to-date windows, while separately checking operating cash generation, leverage, capital expenditures, dividends, share repurchases, and diluted share count.

The filing evidence contains no peer or industry comparison.